Thesis
Development of a modular antibody-degrader conjugate platform for targeted delivery of a Pan-LMO degrader
- Abstract:
-
The LIM-domain-only (LMO) family of proteins play crucial roles in transcriptional regulation and cell differentiation through mediating protein-protein interactions. Dysregulation of LMO proteins has been implicated in multiple human malignancies, including LMO2 in T-cell acute lymphoblastic leukaemia (T-ALL), LMO3 in neuroblastoma, and LMO4 in breast cancer. Despite their therapeutic significance, LMO proteins have long been considered challenging drug targets due to their intrinsically disordered structures.
Previous work in the Russell group led to the discovery of a series of targeted protein degraders targeting LMO2 and resulted in the development of a highly potent small molecule degrader capable of targeting all LMO family members. This provides an opportunity to extend targeted protein degradation beyond T-ALL and investigate the therapeutic potential of degrading LMO4 in breast cancer.
This project aimed to establish a modular antibody-drug conjugate (ADC) platform for the targeted delivery of a pan-LMO degrader to tumour cells. By varying the targeting antibody, this platform has the potential to deliver the same degrader selectively to different cancer types expressing distinct cell-surface antigens. As a proof of concept, trastuzumab was selected to target HER2-overexpressing breast cancer cells and enable the intracellular delivery of the pan-LMO degrader to degrade LMO4.
In this study, four pre-conjugated payloads were successfully designed and synthesised. One payload was subsequently conjugated to trastuzumab to generate a proof-of-concept ADC with an average drug-to-antibody ratio (DAR) of approximately 1. The ADC will be tested in HER2positive BT474 and SKBR3 breast cancer cell lines. More broadly, this work establishes a versatile ADC platform in which the targeting specificity can be readily altered by exchanging the antibody component, enabling selective delivery of the pan-LMO degrader to different tumour types while retaining the same degradation mechanism.
Actions
Access Document
- Files:
-
-
(Preview, Dissemination version, pdf, 10.9MB, Terms of use)
-
(Preview, Supplementary materials, pdf, 6.7MB, Terms of use)
-
Authors
Contributors
+ Russell, A
- Institution:
- University of Oxford
- Division:
- MSD
- Department:
- Pharmacology
- Role:
- Supervisor
- DOI:
- Type of award:
- MSc by Research
- Level of award:
- Masters
- Awarding institution:
- University of Oxford
- Language:
-
English
- Subjects:
- Deposit date:
-
2026-11-12
- ARK identifier:
Terms of use
- Copyright holder:
- Qingqing Ye
- Copyright date:
- 2026
- Notes:
- Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis is derived from this thesis.
If you are the owner of this record, you can report an update to it here: Report update to this record